Suspected non-Alzheimer disease pathophysiology--concept and controversy
about
Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's DiseaseStem Cell Therapy: A Prospective Treatment for Alzheimer's DiseaseAgeing, neurodegeneration and brain rejuvenationOrexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimer's disease-risk genesEffect of LXR/RXR agonism on brain and CSF Aβ40 levels in ratsThe Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Future Directions in Imaging Neurodegeneration.The Intersection of NGF/TrkA Signaling and Amyloid Precursor Protein Processing in Alzheimer's Disease NeuropathologyTau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET studyHippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals."New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS).Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.Outcomes after diagnosis of mild cognitive impairment in a large autopsy series.CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN.17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression.Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease.Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.Lack of a Role for Alzheimer's Disease Pathology in Late-Life Depression, or Just No Relationship With Amyloid?Cerebrovascular pathology and Alzheimer's disease.Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.Elevated Markers of Inflammation Are Associated With Longitudinal Changes in Brain Function in Older Adults.Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging.Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease.Validation of prognostic biomarker scores for predicting progression of dementia in patients with amnestic mild cognitive impairment.Early Tau Burden Correlates with Higher Rate of Atrophy in Transentorhinal Cortex.Blood Pressure's Role in Alzheimer Disease Pathology.Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.Joint associations of β-amyloidosis and cortical thickness with cognition.Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease.Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.
P2860
Q26744646-BFCC48BD-C433-42F8-981D-7F29C09F1567Q28069506-55C781B2-4F5C-4B87-B5F8-F1170BAE953CQ28071590-1CA00FB5-529F-466A-A2E9-EA5A274A3177Q28315261-0C0FADE6-13FE-40EC-8575-289DD5B1526DQ28602802-49702509-FA0B-4BE2-B58D-6439FC0CC646Q31147579-B31A6F00-04E9-4059-B451-07BB0C32BF0CQ31162702-34492D81-E1B5-430F-A0DF-98AFF7069AD5Q33839157-C45A65F7-BB51-40E5-BD36-BA64CAD4BC82Q34550595-78CA0CE6-A0BF-4E2B-B97A-C9D1337AF22FQ37600680-4D25B6AD-9A01-47F3-A81B-5BAAE3DAE689Q38683683-BC1D2EFB-CB08-4766-BF65-22E15CF4D409Q38829043-A55C3760-AA7C-43AC-B2B9-F2A13C765581Q38841003-20E14B44-5F0E-4B66-93EF-982900C4B985Q38893744-E837D00E-CF75-4495-8AFF-1974668FE594Q38948656-9EDDD692-332C-449E-8FC4-062638CC7312Q38965615-EBB60AB4-E2D5-4411-A1DE-48920F721456Q39107119-9F2761E4-E583-43B5-9FA1-C6DD6545B104Q39219904-0A826E38-C825-43C3-A411-778FCE9FDE84Q39275834-790E46C3-7F74-4FBE-B94F-AB73D249E184Q39466317-8EFDDDC8-3A6F-4CA3-8C1C-1126C54D940BQ40045077-6F88E22B-B601-4F2C-9454-4A4C0D03B208Q42255136-223356A9-B25B-44E2-A418-8C9A86B923E8Q42319729-CB0310AE-2D18-48E3-BC0D-630286E53B87Q42374123-8CBA4C1B-3075-4222-A575-83571655934FQ46013646-1B57AFD4-161D-4AD5-890D-6D6C72466791Q46320596-15E52922-9F5C-46D3-9269-DE7E7E10C3B0Q47123978-C2EAFF5A-4C05-4F49-9491-1302A9BC33EBQ47125731-B0CCCD63-588E-4724-A1B1-567F9EC5BD81Q47229656-33B2501D-DAB7-48AA-B787-03FA0A34438CQ47324557-2AFA97C7-7F19-47FD-A92F-5DE4B2528791Q47574138-F6AE52BD-5E64-4C63-8D74-7BD1905E800AQ47980580-F868B33A-3BF8-480A-8B56-3E31914B5AD8Q48020440-0FEFF5A8-7416-4C2C-8ED1-25C391385CD6Q49926296-6B4CAEA8-636A-4055-A99E-27F0245DBBE4Q50034425-6A1DE66F-0910-4F17-8DA4-2D8E4083089FQ50099050-FAF4F207-5CB7-47F3-B2F9-DC8013574116Q50206737-2CBB4D56-A98F-43EF-A086-B721B17455FEQ50422287-EFD6BEEC-4EA4-4A54-A0B9-BF865F6A9366Q50606067-65A823E5-9A64-4A72-ADBE-272564B1B429Q51760876-A337EA7B-41ED-4327-A0B2-954CDF547F78
P2860
Suspected non-Alzheimer disease pathophysiology--concept and controversy
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@ast
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@en
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@nl
type
label
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@ast
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@en
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@nl
prefLabel
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@ast
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@en
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@nl
P2093
P2860
P50
P3181
P1476
Suspected non-Alzheimer disease pathophysiology--concept and controversy
@en
P2093
Dennis Dickson
Elizabeth C Mormino
Gaël Chételat
Pieter J Visser
Reisa A Sperling
Stephanie J B Vos
Victor L Villemagne
P2860
P2888
P304
P3181
P356
10.1038/NRNEUROL.2015.251
P407
P50
P577
2016-02-01T00:00:00Z
P6179
1027476388